About Us

OUR MISSION

Our mission is to advance the development of innovative targeted alpha and beta radiation therapies by leveraging our state-of-the-art 300 m² facilities, including specialized laboratories authorized to work with radiation. Through a highly skilled scientific team and advanced technology, we aim to accelerate research and the creation of new therapeutic solutions that improve health and quality of life.

OUR SCIENCE

At NucliThera, we develop innovative treatments for metastatic cancers by harnessing the power of short-range radionuclides. Our research utilizes high-energy alpha and beta radiation to destroy malignant cells at a microscopic level.
By pairing these radionuclides with cancer-specific targeting molecules, we deliver highly localized radiation exactly where it is needed. This targeted approach ensures effective tumor destruction while preserving surrounding healthy tissue. Through continuous innovation, NucliThera is defining the next generation of targeted radionuclide therapies.

PIPELINE OVERVIEW

Betalutin - Hematological Cancers

Discovery Preclinical Clinical

CD37 Platform

NextGenCD37 - Hematological Cancers

Discovery Preclinical Clinical

CD37 Platform

NT003 - Undisclosed

Discovery Preclinical Clinical

NT002 - Undisclosed

Discovery Preclinical Clinical

Specialized Facilities

•300 m² state-of-the-art premises, including B- and C-class laboratories authorized for work with radiation, alongside offices and meeting rooms.

•Fully equipped laboratories and a specialized scientific team dedicated to the development of novel targeted alpha- and beta-radiation therapies.